YES1 inhibitor

DRUG CLASS:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	NXP900 Sensitive: B - Late Trials NXP900 Sensitive : B	NXP900 Sensitive: B - Late Trials NXP900 Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	NXP900 Resistant: D – Preclinical NXP900 Resistant : D	NXP900 Resistant: D – Preclinical NXP900 Resistant : D
YES1 amplification	Esophageal Squamous Cell Carcinoma	YES1 amplification	Esophageal Squamous Cell Carcinoma	NXP900 Sensitive: D – Preclinical NXP900 Sensitive : D	NXP900 Sensitive: D – Preclinical NXP900 Sensitive : D

Associations(3)